Ophthalmology prior authorization at Horizon Blue Cross Blue Shield of New Jersey
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Horizon Blue Cross Blue Shield of New Jersey ophthalmology PA at a glance
Horizon Blue Cross Blue Shield of New Jersey reviews ophthalmology PA submissions against its medical policy library, with rules drawn primarily from AAO (American Academy of Ophthalmology) Preferred Practice Patterns. Horizon Blue Cross Blue Shield of New Jersey-specific context: Only BCBS licensee in New Jersey; ~3.7M members. OMNIA Health Plans (tiered network) generate frequent appeals — tier-2 hospital usage carries higher cost share. NJ DOBI oversight; NJ has a strong external review program (IHCAP via Maximus).
Documentation packet — what to send
- Diagnosis with ICD-10 (nAMD, DME, RVO, mCNV)
- OCT scan with central macular thickness
- Fluorescein angiography or OCT-A confirming CNV/leakage where required
- Prior anti-VEGF history (drug, doses, intervals, response)
- Visual acuity (Snellen + ETDRS letters)
Common denial patterns to pre-empt
Patterns observed in ophthalmology across payers, and where Horizon Blue Cross Blue Shield of New Jersey's book of business overlaps:
- Anti-VEGF: brand vs compounded bevacizumab (significant cost differential)
- Step therapy: bevacizumab before aflibercept/faricimab
- Dosing interval not policy-compliant (e.g., monthly vs every-8-weeks)
- Diagnosis confirmation (OCT, fluorescein angiogram) not documented
- Loading dose schedule not followed
Appeal angles when Horizon Blue Cross Blue Shield of New Jersey denies
- AAO Preferred Practice Pattern citation
- Anatomic outcome (OCT central macular thickness)
- Functional outcome (visual acuity by ETDRS letters)
- Documented prior anti-VEGF failure
- Diabetic macular edema vs neovascular AMD vs RVO — distinct PA criteria per indication
Peer-to-peer prep
- Bring the latest OCT scan (printed or open in EHR)
- Quote the AAO PPP by year + indication
- For step-therapy through bevacizumab: cite documented failure or contraindication if requesting aflibercept/faricimab first-line
- State whether the dosing is loading (monthly × 3) or maintenance (PRN vs treat-and-extend vs fixed)
Drug-specific PA criteria at Horizon Blue Cross Blue Shield of New Jersey
Deep dives on each drug's PA criteria at Horizon Blue Cross Blue Shield of New Jersey:
Frequently asked questions
What documentation does Horizon Blue Cross Blue Shield of New Jersey need for ophthalmology prior authorizations?
Horizon Blue Cross Blue Shield of New Jersey's PA packet for ophthalmology typically includes: Diagnosis with ICD-10 (nAMD, DME, RVO, mCNV); OCT scan with central macular thickness; Fluorescein angiography or OCT-A confirming CNV/leakage where required; Prior anti-VEGF history (drug, doses, intervals, response). AAO (American Academy of Ophthalmology) Preferred Practice Patterns citations strengthen the submission.
What's the turnaround at Horizon Blue Cross Blue Shield of New Jersey?
Horizon Blue Cross Blue Shield of New Jersey standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which ophthalmology drugs does Horizon Blue Cross Blue Shield of New Jersey most often PA-restrict?
Top targets in ophthalmology: aflibercept, faricimab, ranibizumab. Each follows the per-drug step therapy + documentation requirements published in Horizon Blue Cross Blue Shield of New Jersey's medical policy library.
How do I prep a peer-to-peer with Horizon Blue Cross Blue Shield of New Jersey in ophthalmology?
Bring the latest OCT scan (printed or open in EHR) Quote the AAO PPP by year + indication Have the policy URL and the patient's chart open before the call.
Generate a Ophthalmology PA packet
Open ApprovalHelp — generate a ophthalmology PA packet tailored to Horizon Blue Cross Blue Shield of New Jersey's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com